Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase

Does body weight matter?

Yoshinobu Kanda, Shinichiro Okamoto, Tetsuzo Tauchi, Masahiro Kizaki, Koiti Inokuchi, Mariko Yabe, Kenji Yokoyama, Yoshikazu Ito, Yukihiko Kimura, Masaaki Higashihara, Masami Bessho, Kiyoshi Ando, Shigeru Chiba, Mineo Kurokawa, Kazuo Oshimi, Kazuo Dan, Kazuma Ohyashiki, Yasuo Ikeda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in the chronic phase. However, the feasibility of this dose for small Japanese adults has not been clarified. We prospectively investigated the toxicity and efficacy of this dose in adult Japanese patients. Among the 89 evaluable patients with a median body weight of 62.8 kg, imatinib therapy was held in 40 subjects (45%), due to Grade 3-4 toxicities in 30 patients (75%) and Grade 2 toxicities at the discretion of the attending physician in 10 patients (25%). However, treatment was resumed and the dose was gradually increased until 62 of the 89 patients tolerated a maintenance dose of 400 mg. Older age and lower body weight were significant independent risk factors for discontinuation of imatinib. After a median follow-up period of 31 months, 84 patients were alive without progression. The complete cytogenetic response rate was 60 and 90% at 6 months and 1 year after starting imatinib, respectively. Older patients and those with a lower body weight were less likely to achieve a complete cytogenetic response. These findings suggest that the body weight has a significant influence on the toxicity and efficacy of imatinib in patients with a small body size, although dose reduction in proportion to weight may result in an inadequate response to imatinib.

Original languageEnglish
Pages (from-to)835-839
Number of pages5
JournalAmerican Journal of Hematology
Volume83
Issue number11
DOIs
Publication statusPublished - 2008 Nov

Fingerprint

Leukemia, Myeloid, Chronic Phase
Multicenter Studies
Body Weight
Cytogenetics
Imatinib Mesylate
Body Size
Therapeutics
Physicians
Weights and Measures

ASJC Scopus subject areas

  • Hematology

Cite this

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase : Does body weight matter? / Kanda, Yoshinobu; Okamoto, Shinichiro; Tauchi, Tetsuzo; Kizaki, Masahiro; Inokuchi, Koiti; Yabe, Mariko; Yokoyama, Kenji; Ito, Yoshikazu; Kimura, Yukihiko; Higashihara, Masaaki; Bessho, Masami; Ando, Kiyoshi; Chiba, Shigeru; Kurokawa, Mineo; Oshimi, Kazuo; Dan, Kazuo; Ohyashiki, Kazuma; Ikeda, Yasuo.

In: American Journal of Hematology, Vol. 83, No. 11, 11.2008, p. 835-839.

Research output: Contribution to journalArticle

Kanda, Y, Okamoto, S, Tauchi, T, Kizaki, M, Inokuchi, K, Yabe, M, Yokoyama, K, Ito, Y, Kimura, Y, Higashihara, M, Bessho, M, Ando, K, Chiba, S, Kurokawa, M, Oshimi, K, Dan, K, Ohyashiki, K & Ikeda, Y 2008, 'Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?', American Journal of Hematology, vol. 83, no. 11, pp. 835-839. https://doi.org/10.1002/ajh.21274
Kanda, Yoshinobu ; Okamoto, Shinichiro ; Tauchi, Tetsuzo ; Kizaki, Masahiro ; Inokuchi, Koiti ; Yabe, Mariko ; Yokoyama, Kenji ; Ito, Yoshikazu ; Kimura, Yukihiko ; Higashihara, Masaaki ; Bessho, Masami ; Ando, Kiyoshi ; Chiba, Shigeru ; Kurokawa, Mineo ; Oshimi, Kazuo ; Dan, Kazuo ; Ohyashiki, Kazuma ; Ikeda, Yasuo. / Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase : Does body weight matter?. In: American Journal of Hematology. 2008 ; Vol. 83, No. 11. pp. 835-839.
@article{d716c9f0dff74077abfab8123b275fdb,
title = "Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?",
abstract = "Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in the chronic phase. However, the feasibility of this dose for small Japanese adults has not been clarified. We prospectively investigated the toxicity and efficacy of this dose in adult Japanese patients. Among the 89 evaluable patients with a median body weight of 62.8 kg, imatinib therapy was held in 40 subjects (45{\%}), due to Grade 3-4 toxicities in 30 patients (75{\%}) and Grade 2 toxicities at the discretion of the attending physician in 10 patients (25{\%}). However, treatment was resumed and the dose was gradually increased until 62 of the 89 patients tolerated a maintenance dose of 400 mg. Older age and lower body weight were significant independent risk factors for discontinuation of imatinib. After a median follow-up period of 31 months, 84 patients were alive without progression. The complete cytogenetic response rate was 60 and 90{\%} at 6 months and 1 year after starting imatinib, respectively. Older patients and those with a lower body weight were less likely to achieve a complete cytogenetic response. These findings suggest that the body weight has a significant influence on the toxicity and efficacy of imatinib in patients with a small body size, although dose reduction in proportion to weight may result in an inadequate response to imatinib.",
author = "Yoshinobu Kanda and Shinichiro Okamoto and Tetsuzo Tauchi and Masahiro Kizaki and Koiti Inokuchi and Mariko Yabe and Kenji Yokoyama and Yoshikazu Ito and Yukihiko Kimura and Masaaki Higashihara and Masami Bessho and Kiyoshi Ando and Shigeru Chiba and Mineo Kurokawa and Kazuo Oshimi and Kazuo Dan and Kazuma Ohyashiki and Yasuo Ikeda",
year = "2008",
month = "11",
doi = "10.1002/ajh.21274",
language = "English",
volume = "83",
pages = "835--839",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase

T2 - Does body weight matter?

AU - Kanda, Yoshinobu

AU - Okamoto, Shinichiro

AU - Tauchi, Tetsuzo

AU - Kizaki, Masahiro

AU - Inokuchi, Koiti

AU - Yabe, Mariko

AU - Yokoyama, Kenji

AU - Ito, Yoshikazu

AU - Kimura, Yukihiko

AU - Higashihara, Masaaki

AU - Bessho, Masami

AU - Ando, Kiyoshi

AU - Chiba, Shigeru

AU - Kurokawa, Mineo

AU - Oshimi, Kazuo

AU - Dan, Kazuo

AU - Ohyashiki, Kazuma

AU - Ikeda, Yasuo

PY - 2008/11

Y1 - 2008/11

N2 - Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in the chronic phase. However, the feasibility of this dose for small Japanese adults has not been clarified. We prospectively investigated the toxicity and efficacy of this dose in adult Japanese patients. Among the 89 evaluable patients with a median body weight of 62.8 kg, imatinib therapy was held in 40 subjects (45%), due to Grade 3-4 toxicities in 30 patients (75%) and Grade 2 toxicities at the discretion of the attending physician in 10 patients (25%). However, treatment was resumed and the dose was gradually increased until 62 of the 89 patients tolerated a maintenance dose of 400 mg. Older age and lower body weight were significant independent risk factors for discontinuation of imatinib. After a median follow-up period of 31 months, 84 patients were alive without progression. The complete cytogenetic response rate was 60 and 90% at 6 months and 1 year after starting imatinib, respectively. Older patients and those with a lower body weight were less likely to achieve a complete cytogenetic response. These findings suggest that the body weight has a significant influence on the toxicity and efficacy of imatinib in patients with a small body size, although dose reduction in proportion to weight may result in an inadequate response to imatinib.

AB - Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in the chronic phase. However, the feasibility of this dose for small Japanese adults has not been clarified. We prospectively investigated the toxicity and efficacy of this dose in adult Japanese patients. Among the 89 evaluable patients with a median body weight of 62.8 kg, imatinib therapy was held in 40 subjects (45%), due to Grade 3-4 toxicities in 30 patients (75%) and Grade 2 toxicities at the discretion of the attending physician in 10 patients (25%). However, treatment was resumed and the dose was gradually increased until 62 of the 89 patients tolerated a maintenance dose of 400 mg. Older age and lower body weight were significant independent risk factors for discontinuation of imatinib. After a median follow-up period of 31 months, 84 patients were alive without progression. The complete cytogenetic response rate was 60 and 90% at 6 months and 1 year after starting imatinib, respectively. Older patients and those with a lower body weight were less likely to achieve a complete cytogenetic response. These findings suggest that the body weight has a significant influence on the toxicity and efficacy of imatinib in patients with a small body size, although dose reduction in proportion to weight may result in an inadequate response to imatinib.

UR - http://www.scopus.com/inward/record.url?scp=55549127592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549127592&partnerID=8YFLogxK

U2 - 10.1002/ajh.21274

DO - 10.1002/ajh.21274

M3 - Article

VL - 83

SP - 835

EP - 839

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 11

ER -